PFE
$26.97-0.44 (-1.61%)
Pfizer Inc.
Recent News
Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook
Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic castration sensitive prostate cancer. The company plans to seek expanded global approvals to use the combination in earlier stage prostate cancer settings. The update highlights a potential expansion of TALZENNA’s approved use beyond current indications. For investors watching NYSE:PFE at a share price of $26.97, this update sits within a mixed performance profile...
Why Pfizer (PFE) Dipped More Than Broader Market Today
In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding trading day.
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the latest study.
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
My Top 3 Drug Stocks for March 2026
These companies have impressive track records of navigating the biggest challenges in their industry.